B7-H1, a prognostic factor for patient's response to therapy of acute myeloid leukemia.
- Author:
Wan-Jun SUN
1
;
Xin LI
Author Information
1. Department of Hematology, The Second Artillery General Hospital, Beijing 100088, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
B7-H1 Antigen;
genetics;
Case-Control Studies;
Female;
Gene Expression;
Humans;
Leukemia, Myeloid, Acute;
diagnosis;
genetics;
Male;
Middle Aged;
Prognosis;
RNA, Messenger;
genetics;
Recurrence;
Reverse Transcriptase Polymerase Chain Reaction;
Young Adult
- From:
Journal of Experimental Hematology
2012;20(6):1332-1335
- CountryChina
- Language:English
-
Abstract:
This study was aimed to detect the expression of B7-H1 gene in the acute myeloid leukemia (AML) cells and to explore its clinical significance. The B7-H1 gene expression was detected by real-time quantitative PCR in bone marrow mononuclear cells (BMMNC) from 40 newly diagnosed AML patients, 10 normal volunteers and 10 relapsed patients. The results showed that the expression of B7-H1 from de novo AML patients was lower than that from the normal volunteers, but it was higher in the relapsed patients. The expression level of B7-H1 gene before therapy was significantly higher in non CR patients than that in CR patients after therapy. It is concluded that there is a correlation between the expression level of B7-H1 gene and response to therapy.
